<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02747017</url>
  </required_header>
  <id_info>
    <org_study_id>INSIGHT 007</org_study_id>
    <nct_id>NCT02747017</nct_id>
  </id_info>
  <brief_title>Observational Study of C. Diff in Post-Transplant Patients</brief_title>
  <acronym>CDIFF</acronym>
  <official_title>An International Prospective Observational Study to Assess the Characteristics and Outcomes of Post-transplant Patients Treatment for C. Difficile Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen HIV Programme</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington D.C. Veterans Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this observational study is to estimate the 90-day response rates to
      treatment for a first episode of C. difficile infections (CDI) in adult transplant
      recipients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this observational study is to estimate the 90-day response rates to
      treatment for a first episode of C. difficile infections (CDI) in adult transplant
      recipients. This includes treatment success, recurrence, and complications in a prospectively
      followed cohort of solid organ and hematopoietic stem cell transplant patients. Patients who
      develop CDI within 2 years after transplantation will be enrolled and followed prospectively
      for 90 days after enrollment. Specimens of stool and serum collected within 48 hours of
      initiation of treatment will be stored locally for future epidemiologic studies to examine
      the immunologic and microbiologic risk factors for relapse and treatment failure, as well as
      complications of CDI in the transplant population. Response rates will be classified by organ
      type, hematopoietic stem cell transplant typ, treatment regimen, and immunosuppressive
      regimen.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Response to antibiotic treatment for CDI: clinical cure</measure>
    <time_frame>90 days</time_frame>
    <description>The planned first course of CDI treatment was completed with resolution of symptoms or less than 3 loose stools per day for at least two consecutive days maintained until end of treatment and two days after treatment course ended.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response to antibiotic treatment for CDI: sustained clinical cure</measure>
    <time_frame>90 days</time_frame>
    <description>Clinical cure achieved and maintained for 40 days post treatment initiation without recurrences, complications, ICU with CDI, or death as defined below</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response to antibiotic treatment for CDI: global cure</measure>
    <time_frame>90 days</time_frame>
    <description>Clinical cure achieved and maintained for 90 days post treatment initiation without recurrences, complications, including ICU with CDI, or death as defined below.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response to antibiotic treatment for CDI: relapse</measure>
    <time_frame>90 days</time_frame>
    <description>A new episode of CDI after clinical cure and within 4 weeks after treatment initiation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response to antibiotic treatment for CDI: reinfection</measure>
    <time_frame>90 days</time_frame>
    <description>A new episode of CDI after clinical cure and beyond 4 weeks after treatment initiation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response to antibiotic treatment for CDI: complications</measure>
    <time_frame>90 days</time_frame>
    <description>The study will collect the incidence of specific complications as assessed by the site investigator: perforation of the colon; development of toxic megacolon; need for abdominal surgery related to CDI; transfer to the ICU with CDI; death from CDI-related cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Describe patients who are successfully treatment for CDI</measure>
    <time_frame>90 days</time_frame>
    <description>Patients will be described by demographics (age, race, sex), type of transplant received, specific treatment for CDI, and the strain of C. difficile with which they were infected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe differences in antibiotic regimens and other CDI treatments across geographic regions (US, Europe, South America)</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to treatment for CDI (as defined above) by treatment regimen</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to treatment for CDI (as defined above) by type of transplant (solid organ vs. hematopoietic/stem cell)</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assay differences across sites</measure>
    <time_frame>90 days</time_frame>
    <description>Describe assays used to detect C. difficile organisms and toxin in stool by site at which participants are enrolled.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Clostridium Difficile</condition>
  <arm_group>
    <arm_group_label>CDI patients</arm_group_label>
    <description>Adults with a first episode of CDI within 2 years after solid-organ or stem-cell transplant.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, stool
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with a first episode of CDI within 2 years post solid-organ or stem-cell transplant.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Signed informed consent

          -  Transplant recipient (solid organ, stem cells, or bone marrow) within past 2 years

          -  Currently diagnosed with first CDI after transplant, defined by (1) presence of
             diarrhea (at least 3 loose stools within a 24-hour period), AND (2) detection of C.
             difficile cytotoxin in stools by cytotoxin assay, or toxigenic culture, or polymerase
             chain reaction (PCR) testing for toxin, or enzyme immunoassay, or endoscopic presence
             of pseudomembranes with the detection of C. difficile in tissue biopsies

        Exclusion Criteria:

          -  Previous episode of CDI anytime after transplant

          -  Current treatment for another infectious cause of diarrhea (bacterial, viral, or
             parasitic) at the time of the current CDI diagnosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Michel Molina, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Saint-Louis, Service de Maladies Infectieuses</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gary Collins, MS</last_name>
    <phone>612-626-9006</phone>
    <email>gary-c@ccbr.umn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eileen Denning, MPH</last_name>
    <phone>612-626-8049</phone>
    <email>eileen@ccbr.umn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Casey Dahl</last_name>
      <phone>612-626-3798</phone>
      <email>dahl0465@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Jo-Anne Young</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary A. Johnson, CCRP</last_name>
      <phone>507-538-6511</phone>
      <email>johnson.mary15@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Zelalem Temesgen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maryann Najdzinowicz</last_name>
      <phone>215-662-4007</phone>
      <email>maryann.najdzinowicz@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Emily A Blumberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Kessinger</last_name>
      <phone>412-634-8330</phone>
      <email>kessingercj@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Alison Morris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana de Paz Sierra</last_name>
      <phone>54.11.49590393</phone>
      <email>mariana.depaz@hospitalitaliano.org.ar</email>
    </contact>
    <investigator>
      <last_name>Laura Barcan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHIP, Department of Infectious Diseases, Section 2100</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jens D. Lundgren, MD, DMSc</last_name>
      <phone>45.35.45.57.51</phone>
      <email>jens.lundgren@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Jens D. Lundgren, MD, DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik I fur Innere Medizin der Universitat zu Koln, Studienburo fur Infektiologie u. HIV</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gerd Fatkenheuer, MD</last_name>
      <phone>49.221.478.5860</phone>
      <email>gerd.faetkenheuer@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Gerd Fatkenheuer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana Gonzalez</last_name>
      <phone>34.93.227.55.74</phone>
      <email>agonzal1@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Jose Ma Gatell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Doce de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angel Portillo Fernandez</last_name>
      <phone>34.91.779.22.18</phone>
      <email>portillovih12@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rafael Rubio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://insight.ccbr.umn.edu/i07/</url>
    <description>INSIGHT network website, CDIFF home page</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2016</study_first_submitted>
  <study_first_submitted_qc>April 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2016</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>transplant</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://insight.ccbr.umn.edu/official_documents/CDIFF/protocol_documents/I7-Protocol.pdf</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

